Sign In
Buy FULC
$3.50
-0.0900 (-2.51%)
At Close: Jul 10, 2026
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky
09:00am, Tuesday, 09'th Jun 2026
Fulcrum Therapeutics, Inc. stock lost roughly half its value after the FDA flagged class-wide safety concerns about the entire PRC2 inhibitor drug class -- forcing immediate discontinuation of pocired
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 05'th Jun 2026
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)
09:00am, Friday, 05'th Jun 2026
Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate Fulcrum T
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
02:53pm, Thursday, 04'th Jun 2026
NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PR
What's Going On With Fulcrum Therapeutics Stock On Thursday?
10:22am, Thursday, 04'th Jun 2026
Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant challenges following its decision to discontinue pociredir, its lead experimental drug for sickle cel
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
12:01pm, Wednesday, 03'rd Jun 2026
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations
09:00am, Wednesday, 03'rd Jun 2026
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) lost approximately 50% of it
Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities la
FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc.
11:37am, Tuesday, 02'nd Jun 2026
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
06:39am, Tuesday, 02'nd Jun 2026
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk con
FULC Stock Crashes After Hours: What Investors Need To Know
01:50am, Tuesday, 02'nd Jun 2026
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
05:10pm, Monday, 01'st Jun 2026
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viab
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
04:05pm, Monday, 01'st Jun 2026
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk p
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
10:35am, Wednesday, 20'th May 2026
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
